Evolent Health, Inc. announced on August 18, 2025, its intention to offer $140.0 million in aggregate principal amount of convertible senior notes due 2031. Additionally, the company plans to grant initial purchasers an option to buy up to an additional $20.0 million in notes. The notes are aimed at qualified institutional buyers under Rule 144A of the Securities Act of 1933. Evolent intends to use up to $100.0 million of the net proceeds to repurchase a portion of its 1.50% convertible senior notes due 2025, and approximately $40.0 million to repurchase shares of its Class A common stock. The notes and any Class A common stock issuable upon conversion are not registered under the Securities Act or any state securities laws.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.